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Summary A monoclonal antibody raised against the high molecular weight melanoma antigen was labelled
with indium-ill and injected intravenously into 25 patients with malignant melanoma. The results obtained
from images at 24 and 96h post i.v. administration of the antibody were compared with results obtained from
computerised tomography studies with regard to detection of previously unrecognised sites of metastatic
disease and apparent false positive localisation. Detailed study of the patients' clinical condition and detection
rates using the two methods suggest that both methods detect approximately 80% of clinically and
pathologically confirmed metastases. Of 62 known metastases, the antibody detected 50 (81%), with 17 false
positive results. False negatives were most common in the lung. In eight patients the two methods were
considered of equal value, in 10 the monoclonal gave a greater amount ofclinically relevant information, and
in seven the CT was superior. In three patients clinically significant metastatic lesions were detected by the
radiolabelled monoclonal and had not been previously recognised either by CT scanning or on clinical
grounds. No patients had any adverse reaction to the antibody and in the course of our study the dose of
antibody was reduced from 20mg to 200pg with no apparent loss of sensitivity. In at least two patients
uptake of the labelled monoclonal into tumour sites would have been adequate for effective targeted
radiotherapy.
There are now a large number of antimelanoma murine
monoclonal antibodies available. A number of these have
been analysed in detail with regard to their sensitivity and
specificity in tissue sections, and more recently a number
have been used for pilot studies with an appropriate radio-
label to assess their value in in vivo detection of previously
unrecognised tumour sites. The two antibodies which to date
have been most widely used are antibodies raised against the
high molecular weight antigen (240,000) (Buraggi et al.,
1985; Siccardi et al., 1986; Cerny et al., 1987; Kirkwood et
al., 1988) and the antibody 96.5 which identifies the P27
molecule thought to be transferrin (Lotze et al., 1986). The
reported studies with these two groups of monoclonals differ
greatly in the dose of radiolabelled antibody used and in the
radiolabel. To date iodine-131, indium-111 and technetium-
99m have all been used in various combinations. Some
workers have reported use of whole antibody while others
have claimed greater sensitivity and specificity with Fab or
F(ab)2 fragments. A recent review has suggested that overall
the anti P97 antibody detects 67% of clinically recognised
tumour deposits, and that antibody raised against the high
molecular weight antigen recognises 80% of such tumour
deposits (Larson, 1987).
None of the publications in the literature to date give an
account of a clear comparison of the value of radiolabelled
monoclonal imaging by comparison with computerised
tomography. In most centres CT scanning is the currently
accepted method of staging patients with known or sus-
pected metastatic malignant melanoma. We have therefore
set out to investigate the relative value of CT scanning and
the use of monoclonal antibody scans in 25 patients with
malignant melanoma.
Materials and methods
Antimelanoma antibody
The monoclonal antibody used was XMMME-001, kindly
made available to us by Xoma Corporation. The hybridoma
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cell line secreting this antibody was developed by use of
parent myeloma cell line P3-X63-AG8 which was derived
from a transplantable plasmacytoma of BALB-C origin.
Cultured human melanoma cells were injected into BALB-C
mice, and mouse splenocytes were used for hybridisation.
The resultant antibody is an IgG 2a and recognises the high
molecular weight antigen. Extensive screening of frozen
samples of human tissues using the immunoperoxidase tech-
nique indicated that the antibody reacted strongly with
frozen sections of the great majority of melanoma samples
studied and showed little or no reactivity with the majority
of other tumours or normal tissues. In adults reactivity
comparable in intensity to that seen in melanoma tissue was
observed in vascular endothelium and in some nerve cells,
with lesser degrees of reactivity in some liver samples and in
hair follicles.
Patients
Twenty-five patients with stage 2 or stage 3 malignant
melanoma gave informed consent for entering into the study
for which local Ethical Committee approval and ARSAC
approval was obtained. One patient (case 3) died within 24h
of administration of the antibody from causes not thought
to be related to antibody administration. The first 16
patients, including this patient excluded, were allocated on a
random basis to a 1, 5 or 20mg protein dose. The material
was supplied already covalently coupled to DTPA cyclic
anhydride. The conjugate was presented as a sterile apyroge-
nic solution in 10mM HEPES buffer, 0.15M sodium chloride
(pH 7) at a concentration of 1 mgml-1. Radiolabelling was
carried out by adding 0.2ml of sodium acetate buffer to 70-
90MBq per 0.2ml of indium-111 (Amersham International
plc). Between 1 and 20ml of conjugate solution were added
and the mixture incubated at 4°C for 30min. One millilitre
of 20% HSA solution was added and made up to a final
volume of 27ml with sterile saline prior to passage through a
0.22pm filter. The dose was administered by slow intrave-
nous injection over 3-4min.
All glassware used was washed carefully in acid and rinsed
in distilled demineralised water before use and all solutions
were freshly prepared.
When the images of the first 16 patients were analysed it
was apparent that good imaging could be obtained at the
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lowest dose of protein used (1 mg). The remaining nine
patients were therefore allocated to either a 1 mg dose of
protein (two patients) or to 200Mg of protein (seven
patients). This modification was to determine the lowest dose
at which adequate images could be obtained, and also to
determine whether or not at this low level of foreign protein
a significant antimurine response could be detected. For
these nine patients radiolabelling was carried out in the
original indium-111 vial, to which 0.2ml of sterile 0.2 M
sodium citrate buffer (pH 5) was added together with 0.2 or
1 ml of the antibody conjugate. The mixture was incubated
initially for the recommended period of 6h at 4°C. Chroma-
tographic studies showed that there was no increase in
labelling efficiency beyond 2h and so this period was used in
preparing the patient doses.
An aliquot of each preparation was submitted to thin
layer chromatography (TLC) before administration and the
product would have been rejected if the labelling efficiency
had fallen below 90%. The mean labelling efficiency in the
trial was 97% with no significant difference being found
between the two formulations.
All patients received skin testing with 100,ug of non-
radioactive antibody before receiving the radiolabelled dose
by the intravenous route. No patient showed either an
immediate or a delayed hypersensitivity response to murine
protein. No patient gave any history of having received
murine protein in the past by any route.
Radionuclide imaging was carried out at 24 and 96h post-
injection in every patient, with additional scans at 4, 48 and
72h if feasible, using a Siemens Orbiter tomographic
gamma-camera fitted with a medium energy collimator and
connected online to a Nodecrest computer system. Anterior
and posterior whole body planar images were obtained
routinely as a series of static views, with additional planar
views and emission tomography carried out as indicated.
Each planar view contained at least 100,000 counts, giving
typical collection times of 1-5min for the images at 24h,
rising to 2-10min at 96h. Due to the low counting rates,
tomographic studies were acquired at 64 x 64 resolution over
64 angles for 45s per view, typically containing 75,000
counts.
Because of the high liver/spleen uptake which was found
in the first two patients, a conventional colloid radionuclide
scan was added to the protocol to assist interpretation of the
antibody images. This was carried out 96h after injection of
the antibody for these two patients, but within 24h before
injection of the antibody in the remainder.
In order to ascertain the blood clearance rates of the
radiolabelled antibody, 5ml blood samples were obtained at
various times post-injection. These samples were centrifuged
to separate red cells and plasma and the radioactivity in each
component was assayed separately. The results were norma-
lised for radioactive decay by counting a standard prepared
from the dose residue with each sample.
Biokinetic data to enable dosimetric calculations to be
carried out were obtained by drawing regions-of-interest
around each of the major organs on the appropriate planar
images and noting the total counts within each. This was
carried out for both anterior and posterior views and the
geometric mean of the two values for each organ calculated.
The mean was then multiplied by 1.8, a factor to take
account of absorption in a 220mm thick body relative to a
source in air, which was determined experimentally for
indium-Ill. The data from each set of images were further
normalised for radioactive decay and possible variations in
gamma-camera sensitivity by imaging a standard each time
the patient was imaged.
Before administration of the radiolabelled monoclonal, all
patients had a full clinical examination, standard investi-
gations including chest X-ray and haematological and bio-
chemical routine testing. CT scans were carried out on the
chest and abdomen of all patients within 7 days of imaging.
Results
Table I summarises the clinical findings, CT results and
imaging results, and gives an indication of the relative
clinical value of the antibody and CT scans. In our 25
patients 62 deposits were known to be present, and imaging
detected 50 (81%) of these. Seventeen areas of high uptake
were considered false positives, and there were four true
negatives. The CT scan and nuclear medicine studies were
reported separately by observers with no knowledge of the
other test results. The individual reporting the scintigram
was given minimal clinical information.
In general, a good correlation was obtained between
clinical observations, CT scanning and imaging. Neither CT
scanning nor imaging were clearly superior methods. Imag-
ing does of course have the advantage ofgiving a scan of the
entire body while CT as routinely performed in our institu-
tion shows only the chest and abdomen. For the limbs this
was rarely a positive advantage in that uptake noted by the
scintigrams in the limbs was in all cases found in tumour
sites already detected by clinical examination. Figure 1
shows an image in a tumour-free individual.
Three clear examples of situations in which scintigrams
gave information not observed by clinical examination or CT
were cases 4, 21 and 24. Patient 4 showed an unexpected hot
spot in the right parietal area on imaging (Figure 2). No
relevant clinical symptoms or signs had been noted on
general examination before imaging, and a second detailed
CNS examination carried out after the results of the imaging
were made available to the clinicians again failed to show
any localising signs. A CT scan of the head (Figure 3) and
neck confirmed the presence of an isolated metastatic lesion
which was excised within 3 days of both tests and patho-
logically confirmed to be metastatic melanoma. Patient 21
complained of severe back pain with a normal X-ray of the
spine. The scintigram showed a suspicious area around
thoracic vertebrae 7-8. This was not seen on the first CT
scan, but was confirmed on a second optimised CT scan of
the area. The patient subsequently had radiotherapy to this
area with significant pain relief. Patient 24 had a negative
CT scan, negative bone scan and negative NMR but showed
a hot spot in the soft tissue of his left upper femoral area.
Two months after this image was obtained he presented with
tumour in the left inguinal nodes.
In a number ofpatients, clinically obvious tumour was not
detected by the radiolabelled monoclonal antibody. This
included the gross pulmonary involvement confirmed at post
mortem in patient number 3. As this patient died within 48h
of administration of the radiolabelled monoclonal antibody,
only 24h images are available, but they show no uptake in
the lungs. In a number of situations the imaging technique
detected possible tumour deposits which, with prolonged
follow-up of the patients from 6 to 18 months after scan-
ning, appear to have been false positive images. The areas
most commonly involved include the scrotal area in males,
which has been noted by other observers, a diffuse pattern
over the skull in patients 1 and 21 and isolated areas of
apparent increased uptake over bony areas such as the
sterno-clavicular joints and the small joints of the feet.
Subsequent clinical examination of patients 11 and 20 who
both showed this pattern, did not indicate the presence of
any inflammatory lesion which might have contributed to
non-specific uptake. In two patients, large solitary lung
metastases were not shown on imaging and, in a further
four, multiple small pulmonary metastases were not visual-
ised. Of seven patients with pulmonary metastases, the
lesions were seen only in one on the image.
The aim of this study was to determine the relative value
of computerised tomography and use of a radiolabelled
monoclonal antibody to localised disease sites. In eight
patients examined in this study the information obtained was
of equal value using both techniques. In 10 patients the602 R.M. MACKIE et al.
Table I Cases studied: CT and radiolabelled antibody findings
Patient no.
and dose Clinicalfindings and X-ray CT Image Comments
1 mg Nodes R. groin R. common iliac chain Frontal bones skull 1 TP, 3FP
Subcutaneous nodules pelvis
and R. thigh
2 5mg Gross involvement liver and
lungs
3 20mg Gross pulmonary
PM extensive lung spread
4 5mg Liver secondaries
Nil after surgery
5 subcutaneous nodules legs
7 20mg R. upper femur
C3 metastases on X-ray
CNS symptoms
8 1 mg Metastatic nodes L. groin
removed I week previously
9 20mg R. calf
10 20mg Dizziness and unsteady gait
11 5g Secondary removed from
calf 1 week previously.
No known primary.
12 1 mg Known liver metastases.
CNS symptoms.
13 20mg Ocular primary
14 5mg Chest X-ray L. hilar mass
15 1 mg Secondaries in liver, lungs,
R. orbit, CNS
16 20mg CNS
Chest X-ray R. lung
17 200 pg 6th nerve palsy
Positive bone scan skull
18 200pg L. hilar mass
19 200pg Previously excised
secondary L. flank
20 200 pg L. pleural disease
21 1 mg Back pain
Normal chest X-ray
22 200,g Hepatomegaly, R. retro-
orbital, Spinal involvement
on X-ray, 3 axillary lesions
23 1 mg Nil post-surgery
24 200 pg No obvious tumour
post-surgery
NMR negative
25 200 pg Bone scan L. iliac crest
Chest X-ray multiple lung
metastases
Severe back pain L3 area
enlarged
Base R. lung, pleura
and mediastinum
Liver 5-6 metastases
Nodes aortic bifurcation
Lungs, ?tuberculosis,
?tumour
Large liver
Multiple lung metastases
Later R. parietal+
Nil
CT negative
R. axilla and chest wall
L. lower brain stem
R. psoas
mass?, doubtful
?R. mid zone chest
R. parietal lesion
R. chest, Liver
CT negative
Liver
L. parietal
CT negative
R. mid zone chest
L. lower lobe
L. side scrotum
L. pubic symphysis
Multiple lung and liver
R. cerebellum, R. orbit
R. parietal,
L. parietofrontal
Brain metastases and lung
CT negative
L. lower lobe and
para-aortic
CT negative
L. chest wall positive
R. 4ung, L. periaortic
L. external iliac
2nd scan, ?dorsal
vertebrae
Hepatic metastases
CT negative
CT negative
L. side chest
Apex L. lung
L. axilla
R. groin, L. femur
L. abdomen
R. chest
R. tibia and foot
R. lobe liver
R. sternoclavicular
L. tibia
Liver and spleen
R. parietal, Scrotum,
L. knee, R. ankle
Nil
L. anterior chest
R. cerebellum
5 leg lesions
Liver
R. chest, both femurs
Hot spot L. groin
R. calf, L. shoulder
Hilum
R. parietal
L. sternum and shoulder
L. anterior chest
Feet
Liver
L. parietal+2 frontal
L. axilla
L. groin
R. chest
R. lower abdomen
R. orbit R. thigh
L. parietal, cerebellum
R. inguinal and thigh
R. lung, L. frontal and
parietal, 2 lesions R.
thigh, L. lateral chest
Negative
Negative
Negative
L. chest wall. L. sterno-
clavicular joint, R. arm
Normal liver and spleen
Hot spot T8
Liver+
Spleen+
3 axillary lesions
Negative
Lesion top L. femur
L. pelvic area
L. lung
3rd lumbar vertebra
2FP, 2TP
1 FN (lung)
2TP,
1 FN (lung)
3FP, I FN,
3TP, I previously
unsuspected (R. parietal)
TN
5TP, 2FP
4TP, lFP, 1FN
Probable localisation
in granulation tissue
I TP, 2FP
1 TP, 2FN (liver
and lungs)
Tumour-free 18 months
later, therefore 2FP
4TP
Tumour-free 18 months
later, therefore 2FP
2TP, 2FN
4TP, 1FN
8TP, lFN
Died of malignant
melanoma 2 months later,
therefore 1 FN
2FN
Well 6 months later,
therefore 1 TN
3TP
Pain relief after
radiotherapy to T8
5TP
1TN
L. inguinal nodes
positive 2 months later,
therefore 1 TP
3TP
5 1mg
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Figure 2 Image of head and neck area of patient 4, showing
increased uptake in parietal area.
Figure 1 Images obtained with scan of a normal healthy indivi-
dual with no metastatic melanoma.
radiolabelled monoclonal studies gave information not made
available by normal computerised tomography, and in seven
cases computerised tomography was superior. An analysis of
these seven shows an equal distribution between situations in
which the radiolabelled monoclonal failed to localise in
clinically apparent disease sites and situations where appar-
ent false positive localisation occurred.
No patient showed any immediate or longer term adverse
reaction to the injection of foreign protein.
The importance of good radiolabelling efficiency was
demonstrated by the visualisation of renal activity, particu-
larly in the 24h scans, in patients where the labelling
efficiency fell below approximately 95%. This may be attri-
buted to free indium or indium colloid rather than to
indium-DTPA, since the latter would have been excreted into
urine. For therapy, this parameter will be of crucial
importance.
The amount of protein administered might be thought to
have a bearing on the uptake of the radiopharmaceutical.
Table II shows the normalised counting rates obtained at
24h post-injection, excluding patients in whom any extrava-
sation was noted. A total body count index was obtained by
Figure 3 CT scan of patient 4, showing lesion in parietal area.
Histology confirmed metastatic melanoma.
normalising the counts in the standard views obtained 24h
post-injection to a 100 s count time, summing the results and
dividing by the amount of activity administered. It can be
seen that there was no significant effect attributable to the
variation in protein dose, even at the 200pg level.
More than 95% of the activity remaining in the blood was
associated with the plasma fraction from 1 h post-injection
onwards. The blood clearance data can be fitted by a bi-604 R.M. MACKIE et al.
Table II Total body uptake at 24h versus protein
dose
200pg Img 5mg 20mg
8.89 4.44 6.66 7.11
7.47 6.62 6.89 3.45
4.10 10.29 7.77 6.32
6.32 7.03 6.62 7.11
9.62 8.26 7.91
Mean 7.22 6.90 7.17 6.00
s.d. 1.96 2.20 0.62 1.74
Table III Absorbed radiation
dose estimates (pGyMBq 1)
Liver 513
Spleen 1,431
Bone 151
Testes 595
Kidney 684
Total body 95
exponential function, 62% of the activity having a half-time
in blood of 9.6h and the remaining 38% a half-time of
46.8h.
Dosimetry was calculated according to the schema of the
MIRD Committee. Organ uptake was assumed to occur
instantaneously with the biodistribution of activity taken to
be that found at 24h post-injection. Other than the blood,
biological half-life was taken as the physical half-life of the
radionuclide. This will result in an overestimation of the
dose, but the errors involved in the calculations do not
justify more accurate quantification: there were substantial
inter-patient differences in organ uptake. The resulting mean
dose estimates are given in Table III.
The radiation doses are generally higher than those extra-
polated from animal data, particularly for the testes, due to
the cross-reactivity discussed above. The figures are in
general agreement with those given by Taylor et al. (1988)
for a protein dose of 2.5mg of their antibody.
Discussion
These results are similar to previously published studies,
suggesting that using similar monoclonal antibodies which
recognised the high molecular weight antigen, approximately
80% of melanoma deposits can be detected. Siccardi et al.
(1986) suggest that with small lesions of a diameter of 1 cm
or less this detection rate may fall to only 59%. These
authors also suggest that the lung is the most difficult area
from which to obtain accurate images. This correlates with
our own experience, and it may be that altered blood flow
dynamics in and around pulmonary metastases result in poor
perfusion of lung metastases and thus inadequate uptake.
Cerny et al. (1987) suggest that particularly reliable images
are obtained when studying metastatic deposits in bone, liver
and lymph nodes, while lung, stomach and bowel are
difficult areas for imaging. The latter two sites may give rise
to problems with interpretation because of antibody excre-
tion via the gastrointestinal tract. Kirkwood et al. (1987)
comment that a very similar monoclonal antibody is cleared
faster in males than in females or in one castrated male in
their study, and also observe the apparently non-specific
concentration of antibody in testicular tissue. This study also
reports false positive results obtained in bone, heart, breast
and thyroid.
It is possible that SPECT imaging of the thorax and
abdomen routinely at 24h post-injection might contribute to
further specificity and sensitivity of the imaging technique.
Greater use of SPECT would also aid in the more precise
localisation of soft tissue lesions. In particular, this might
improve the diagnostic capability for lesions in lungs and
liver. It should, however, be borne in mind that the indivi-
dual reporting the images in this study had virtually no
clinical information, whereas the CT scans were reported
with full clinical details available. The accuracy of the
imaging reports was noticeably improved in the latter
patients.
An important observation in this study was that at protein
doses of 1 mg and 200gig, no detectable antimurine response
was observed from serum samples taken 28 days post-
injection. This important finding requires confirmation, but
is encouraging in clinical situations where repeated use of
foreign protein might be required. For example, this would
allow imaging studies to be followed by therapeutic admi-
nistration without accelerated clearance of the murine anti-
body. Patients 4 and 22 had tumour uptakes in the range
0.03-0.06% per gram, which would permit cell kill if the
antibody were labelled with a beta- or alpha-emitting radio-
nuclide. Strategies would be required to reduce the non-
target uptake of antibody, particularly that in liver and
spleen. In view of the very poor response of metastatic
melanoma to conventional chemotherapy, this approach to
the management of advanced disease is clearly worthy of
investigation and is in progress.
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